Month: June 2024

European Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancerAlecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive resected non-small cell lung cancer, as demonstrated in the Phase III ALINA study1 Alecensa’s approval addresses an urgent unmet need in the early-stage setting where about half of all people experience disease recurrence following surgery, despite adjuvant chemotherapy2 Early diagnosis and treatment of lung cancer can reduce the burden associated with progressive disease and give people the best possible chance of cure3-6Basel, 10 June 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved Alecensa® (alectinib) monotherapy, as adjuvant...

The test uses highly sensitive PCR technology, requiring only a single nasal-swab sample to provide rapid, accurate qualitative detection and differentiation among four of the most prevalent respiratory viruses for which differential diagnosis can drive appropriate treatment. Enables healthcare professionals to make confident clinical decisions and promptly determine appropriate treatment, with definitive results reported in just 20 minutes. Expands Roche’s extensive molecular point of care testing portfolio, offering greater flexibility to meet testing needs amid evolving regional prevalence of respiratory infections.Basel, 10 June 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its cobas® liat SARS-CoV-2, Influenza A/B &...

Hepsor SPV I Ltd, a Ontario-based subsidiary of Hepsor AS, made its third investment in the Canadian real estate market. An assembly of 7 properties was acquired in the much desired midtown Toronto neighborhood of Leaside, at 17-29 Glenavy Avenue, together with Canadian partners, Elysium Investments Inc. (Elysium). Elysium Glenavy Limited Partnership was formed to develop the property in which, in addition to Hepsor and Elysium, various Canadian and European investors are also participating. Fasken (www.fasken.com), one of Canada’s largest law firms, served as legal counsel for Hepsor, reviewing the partnership agreements and providing advice on deal structure and risk mitigation. The initial phase of the critical path of the project will involve the activation of a best-in-class consultant team led by the project architects, internationally...

This award recognizes leading third-party logistics and cold storage providers in the cold food and beverage industry CHATTANOOGA, Tenn., June 10, 2024 (GLOBE NEWSWIRE) — Food Logistics named Covenant Logistics Group as one of the winners of this year’s Top 3PL & Cold Storage Providers Award, which recognizes leading 3PLs and cold storage providers in the cold food and beverage industry. “3PLs and cold storage providers remain a key puzzle piece to building and nurturing partnerships, cultivating resilience and helping companies in the cold food space overcome supply chain disruptions,” says Marina Mayer, Editor-in-Chief of Food Logistics and Supply & Demand Chain Executive. “Seventy-six percent of the winners plan to invest in software solutions this year. This is indicative of how forward-thinking these 3PLs and cold...

TOKYO and CAMBRIDGE, Mass., June 09, 2024 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the U.S. Food and Drug Administration (FDA) has accepted Eisai’s Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI®) intravenous (IV) maintenance dosing. A Prescription Drug User Fee Act (PDUFA) action date is set for January 25, 2025. LEQEMBI is indicated for the treatment of Alzheimer’s disease (AD) in patients with mild cognitive impairment or mild dementia stage of disease (collectively referred to as early AD). As part of the proposed monthly IV maintenance regimen, the patients who have completed the...

TORONTO, June 09, 2024 (GLOBE NEWSWIRE) — EnviroGold Global Limited (CSE: NVRO | OTCQB: ESGLF | FSE: YGK) (“EnviroGold,” or the “Company”), a technology company enabling the global mining industry to monetize valuable metals contained in mine waste and tailings, reduce environmental liabilities and improve social and environmental outcomes, is pleased to announce that it has closed the first tranche of the previously announced non-brokered private placement and issued 14,600,000 units (the “Units”) at a price of $0.05 per Unit for aggregate proceeds of C$730,000 (the “Financing”). Each Unit consists of one common share (each a “Common Share”) and one warrant (each a “Warrant”) exercisable to acquire one additional Common Share at a price of $0.08 until April 30, 2026. The Company anticipates closing a second tranche of the Financing...

Injection-free subgroup results demonstrated that a single intravitreal dose of 4D-150 without any supplemental anti-VEGF injections resulted in stable mean visual acuity that was equal to or higher than in the standard bimonthly aflibercept control group at all six timepoints through Week 24 Single intravitreal 3E10 vg/eye dose resulted in sustained reduction and stabilization of mean central subfield thickness (CST) compared to aflibercept at all timepointsIn the 3E10 vg/eye injection-free subgroup, the mean difference versus aflibercept in CST change from baseline for Weeks 20 and 24 was -31 microns in favor of 4D-150 Injection-free subgroup analyses reinforce previously reported positive 4D-150 Phase 2 PRISM topline results Interim 24-week landmark analysis from Phase 2 PRISM Population Extension cohort evaluating 4D-150 in broader...

Will send 10 Rogers customers, hockey fans and their guest to Game Four in Edmonton Will co-host game-day concerts with NHL for fans outside Rogers Place Will showcase real-time game updates on digital billboards throughout EdmontonTORONTO, June 08, 2024 (GLOBE NEWSWIRE) — Rogers today announced a national customer contest, Bring Stanley Home, to send Rogers customers and hockey fans from across Canada to the Stanley Cup Final in Edmonton. As the proud partner of the Edmonton Oilers and the NHL, the company will co-host free game-day concerts outside Rogers Place for games 3 and 4. “This is an exciting time for hockey fans across Canada, and we’re thrilled to celebrate Canada’s game with customer contests, concerts, and unique experiences for our customers and hockey fans,” said Terrie Tweddle, Chief Brand and Communications...